| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.TRANSPROCEED.2017.09.042 |
| P698 | PubMed publication ID | 29198659 |
| P50 | author | Klemens Budde | Q72992120 |
| P2093 | author name string | T Dörner | |
| O Staeck | |||
| D Khadzhynov | |||
| F Halleck | |||
| L Lehner | |||
| M Duerr | |||
| E Schrezenmeier | |||
| P2860 | cites work | Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients | Q43288379 |
| Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. | Q45154677 | ||
| HIV-associated lymphoma: promising new results, but with toxicity | Q45301081 | ||
| Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin's lymphoma patients receiving autologous hematopoietic stem cell transplantation | Q46944847 | ||
| Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder | Q74564175 | ||
| Rituximab for the treatment of rheumatoid arthritis | Q80083912 | ||
| The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects | Q26770815 | ||
| Treatment Options for Primary Autoimmune Hemolytic Anemia: A Short Comprehensive Review | Q26773178 | ||
| Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials | Q33315300 | ||
| Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action | Q33370836 | ||
| U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia | Q34157931 | ||
| Rituximab for non-Hodgkin's lymphoma: a story of rapid success in translation | Q34687563 | ||
| The mechanisms of action of rituximab in the elimination of tumor cells | Q35090597 | ||
| CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment | Q35193958 | ||
| Therapeutic strategies targeting B-cells in multiple sclerosis | Q35955099 | ||
| Tolerability and safety of rituximab (MabThera). | Q36212992 | ||
| Infectious complications associated with the use of rituximab for ABO-incompatible and positive cross-match renal transplant recipients | Q36936436 | ||
| The effects of rituximab on immunocompetency in patients with autoimmune disease | Q37046689 | ||
| Infectious complications associated with immunomodulating monoclonal antibodies used in the treatment of hematologic malignancy | Q37101820 | ||
| A review of the current use of rituximab in autoimmune diseases | Q37322846 | ||
| Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. | Q37572815 | ||
| Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options | Q38206175 | ||
| Current role of rituximab in systemic lupus erythematosus | Q38293284 | ||
| A systematic review of the use of rituximab as induction therapy in renal transplantation | Q38306136 | ||
| Biological drugs in ANCA-associated vasculitis | Q38439308 | ||
| Cancer incidence before and after kidney transplantation | Q38464934 | ||
| The effectiveness and safety of rituximab as induction therapy in ABO-compatible non-sensitized renal transplantation: a systematic review and meta-analysis of randomized controlled trials. | Q38580399 | ||
| Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. | Q38673151 | ||
| Future therapies for pemphigus vulgaris: Rituximab and beyond | Q38705147 | ||
| KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary | Q39936645 | ||
| The effect of rituximab dose on infectious complications in ABO-incompatible kidney transplantation. | Q40670409 | ||
| Hepatitis B reactivation and rituximab: a new boxed warning and considerations for solid organ transplantation | Q42233865 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rituximab | Q412323 |
| infectious disease | Q18123741 | ||
| P304 | page(s) | 2269-2273 | |
| P577 | publication date | 2017-12-01 | |
| P1433 | published in | Transplantation Proceedings | Q7834825 |
| P1476 | title | Incidence of Infectious Disease and Malignancies After Rituximab Therapy in Kidney Transplant Recipients: Results From a Cohort in Germany | |
| P478 | volume | 49 |
Search more.